Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our Core Values drive the way we work together:

Dare to Cure
Break Boundaries
Beyond Yourself
Prepare & Execute Relentlessly

Join us in creating the future of genetic medicine.

GENERAL SUMMARY

Reporting to the Chief Medical Officer, the VP Clinical Development, Ophthalmology provides strategic and operational leadership for the global development of ophthalmic genetic medicines in Drug Development.

We seek an experienced physician to play a critical role at 4DMT as we spearhead the introduction of intravitreally delivered genetic medicines for the treatment of the most common causes of irreversible blindness. The VP, Clinical Development will be a primary point person for medical oversight of clinical studies, with responsibilities including medical monitoring, review and interpretation of clinical trial data, clinical trial design, protocol development, and drafting of key clinical documents such as protocols, CSRs, briefing packages, INDs, NDAs, BLAs, MAAs, and other regulatory documents. This role will be responsible for timely execution of deliverables in close collaboration with relevant internal and external partners.

RESPONSIBILITIES

Serve as the primary medical monitor for multiple ophthalmology clinical trials, providing expert oversight of patient safety, data integrity, and protocol adherence throughout study execution.
Direct and mentor a team of medical monitors, ensuring high standards of medical oversight and data review, while maintaining accountability for real-time monitoring activities and timely delivery of critical clinical trial outputs.
Provide medical leadership for cross-functional internal workstreams including pharmacovigilance, biostatistics, clinical operations, regulatory affairs, etc.
Provide oversight and lead teams responsible for development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory response documents, and other regulatory submissions or documents as appropriate.
Collaborate closely with Clinical Operations and be accountable for clinical trial conduct and timelines for associated key deliverables.
Keep up to date with compliance, SOPs and adhere to ICH, GCP, and relevant regulatory guidelines.